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Abstract
Neuroblastoma (NB) is the most common extracranial solid tumor in infants and children, and imposes
significant morbidity and mortality in this population. The aggressive chemoradiotherapy required to
treat high-risk NB results in survival of less than 50%, yet is associated with significant long-term adverse
effects in survivors. Boosting efficacy and reducing morbidity are therefore key goals of treatment for
affected children. We hypothesize that these may be achieved by developing strategies that both focus
and limit toxic therapies to the region of the tumor. One such strategy is the use of targeted image-guided
drug delivery (IGDD), which is growing in popularity in personalized therapy to simultaneously improve
on-target drug deposition and assess drug pharmacodynamics in individual patients. IGDD strategies can
utilize a variety of imaging modalities and methods of actively targeting pharmaceutical drugs, however in
vivo imaging in combination with focused ultrasound is one of the most promising approaches already
being deployed for clinical applications. Over the last two decades, IGDD using focused ultrasound with
“microbubble” ultrasound contrast agents (UCAs) has been increasingly explored as a method of
targeting a wide variety of diseases, including cancer. This technique, known as sonopermeation,
mechanically augments vascular permeability, enabling increased penetration of drugs into target tissue.
However, to date, methods of monitoring the vascular bioeffects of sonopermeation in vivo are lacking.
UCAs are excellent vascular probes in contrast-enhanced ultrasound (CEUS) imaging, and are thus
uniquely suited for monitoring the effects of sonopermeation in tumors.
Methods: To monitor the therapeutic efficacy of sonopermeation in vivo, we developed a novel system
using 2D and 3D quantitative contrast-enhanced ultrasound imaging (qCEUS). 3D tumor volume and
contrast enhancement was used to evaluate changes in blood volume during sonopermeation. 2D
qCEUS-derived time-intensity curves (TICs) were used to assess reperfusion rates following
sonopermeation therapy. Intratumoral doxorubicin (and liposome) uptake in NB was evalauted ex vivo
along with associated vascular changes.
Results: In this study, we demonstrate that combining focused ultrasound therapy with UCAs can
significantly enhance chemotherapeutic payload to NB in an orthotopic xenograft model, by improving
delivery and tumoral uptake of long-circulating liposomal doxorubicin (L-DOX) nanoparticles. qCEUS
imaging suggests that changes in flow rates are highly sensitive to sonopermeation and could be used to
monitor the efficacy of treatment in vivo. Additionally, initial tumor perfusion may be a good predictor of
http://www.thno.org
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drug uptake during sonopermeation. Following sonopermeation treatment, vascular biomarkers show
increased permeability due to reduced pericyte coverage and rapid onset of doxorubicin-induced
apoptosis of NB cells but without damage to blood vessels.
Conclusion: Our results suggest that significant L-DOX uptake can occur by increasing tumor vascular
permeability with microbubble sonopermeation without otherwise damaging the vasculature, as
confirmed by in vivo qCEUS imaging and ex vivo analysis. The use of qCEUS imaging to monitor
sonopermeation efficiency and predict drug uptake could potentially provide real-time feedback to
clinicians for determining treatment efficacy in tumors, leading to better and more efficient personalized
therapies. Finally, we demonstrate how the IGDD strategy outlined in this study could be implemented in
human patients using a single case study.
Key words: Sonoporation, sonopermeabilization, sonopermeation, neuroblastoma, quantitative contrastenhanced ultrasound (qCEUS), image-guided drug delivery.

Introduction
Neuroblastoma (NB) is the most prevalent
extracranial solid tumor in infants and children. NB
most often originates in the adrenal gland [1] and is
diagnosed at a median age of 22 months. This
malignancy is responsible for 15% of all childhood
cancer deaths [2]. High-risk NB is currently treated
with
maximally
intense
chemoradiotherapy,
immunotherapy, and autologous stem cell transplant
[3,4]. Despite this, about half of the afflicted patient
population will die of this disease [5]. For survivors,
this intense therapy is associated with long-term
toxicities [6]. For example, doxorubicin – which is a
key component of multiagent chemotherapy for
aggressive NB – is implicated in both acute and
chronic adverse effects, including life-threatening
cardiotoxicity [7]. Therefore, methods of improving
chemotherapeutic delivery are sorely needed to
achieve better efficacy and reduce systemic toxicity.
One approach to this goal has been the
development of nanomedicines to improve the
circulation of drugs and payload into tumors. This
strategy employs carrier vehicles with diameters
between 10 and 200 nm to convey therapeutic drugs,
which can either actively or passively target tumors in
vivo. Currently, the most common method of targeting
nanomedicines to cancers is by passive accumulation
via the well-described Enhanced Permeability and
Retention (EPR) effect [8]. The EPR effect is commonly
attributed to aberrant tumor vasculature, which is
leaky (allowing ingress) and deficient in lymphatics
(restricting drainage), causing long-circulating
nanomaterials (between 50 and 750 nm) to gradually
accumulate [9–11]. This strategy was exploited in the
first FDA-approved nanomedicine, liposomal
doxorubicin (L-DOX) or Doxil™, which was
developed to extend the circulating half-life of
doxorubicin, enhancing both deposition of drug
payloads within tumors and reducing drug
cardiotoxicity [12]. While this approach has been
shown to function in specific cancer types, the use of

nanomedicines such as L-DOX has not had the
anticipated impact of significantly extending patient
survival [13,14].
Furthermore, various studies have discovered
the EPR effect to be highly dependent on the cancer
type and stage [15]. The extent of the EPR effect has
been demonstrated to be highly exaggerated in
xenograft tumor models, with less reliable efficacy in
clinical cancers [16–18]. Given this reality, novel
strategies must be pursued to enhance the
intratumoral accumulation of doxorubicin and other
chemotherapeutics. More efficient delivery of
circulating drugs could also cut down off-target
adverse effects by reducing required systemic dosages
for therapy [19]. In these studies, we show that
ultrasound-based IGDD holds promise as a means of
achieving these therapeutic goals.
One promising method of overcoming reliance
on the EPR effect utilizes the combination of
ultrasound contrast agents (UCAs, also known as
microbubbles) and focused ultrasound. Microbubbles
are sound-sensitive gas-filled spheres (1-10 µm in
diameter) that can mechanically disrupt cell bilayers
or cellular gap junctions, allowing increased uptake of
circulating drugs [20–23]. Numerous studies have
established that volumetric oscillation of the UCA in
an ultrasound field can promote intracellular uptake
of drugs by a membrane-permeabilizing process
known
as
“sonopermeation”
(also
termed
“sonoporation” or “sonopermeabilization”) [24–26].
This technique has been utilized to achieve improved
intracellular delivery of a wide variety of therapeutic
compounds, including proteins [27], DNA [28–32],
and nanoparticles such as liposomal doxorubicin [33,
34].
Despite these advances, nanoparticle delivery to
cancer in vivo remains challenging. Physical
co-treatments such as sonopermeation have
progressively been adopted for applications such as
blood-brain barrier (BBB) opening [35]; Aryal et al
http://www.thno.org
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doubled DOX concentrations in rat gliomas by
co-injecting L-DOX with microbubbles and sonicating
with focused US [36]. Nevertheless, to date, only a few
groups have employed sonopermeation in vivo to
enhance L-DOX delivery to tumors beyond the brain.
Theek et al showed that sonopermeation could
improve intratumoral drug penetration, even in
tumor models characterized by extensive stromal
compartments and dense collagen networks [37].
Tinkov et al illustrated that sonopermeation caused
preferential uptake of doxorubicin in tumors, and
noted a 12-fold increase in intratumoral drug
concentration following sonopermeation [38]. The
majority of these studies used microscopy and tissue
extraction procedures to quantify drug accumulation,
quantifying tumor growth curves by physical caliper
measurements [39]. Thus, a major obstacle to
implementing sonopermeation therapy in clinical
practice is that ex vivo analysis currently functions as
the only method to quantify drug uptake and monitor
its bioeffects.
In the context of ultrasound-triggered
microbubble destruction (UTMD), passive cavitation
detection is being investigated as a technique to map
acoustic emissions in order to calculate stable and
inertial cavitation doses [40]. This technique assumes
that the risk of vascular damage correlates with
increasing cavitation doses, but it doesn’t accurately
map the bioeffects associated with sonopermeation,
since it focuses primarily on cavitation responses of
the bubbles. Conversely, perfusion kinetics are
dictated by the biology of the vasculature itself, and
thus hold the potential to divulge the degree to which
sonopermeation has altered vascular architecture and
flow characteristics. We therefore set about to monitor
sonopermeation efficacy in vivo using real-time
perfusion imaging as feedback. Our study aimed to
accomplish three objectives: (1) to demonstrate that
sonopermeation can efficiently increase L-DOX
uptake in tumor tissue (using a orthotopic
neuroblastoma xenograft model), (2) to gauge
whether
perfusion
kinetics
can
predict
sonopermeation-induced efficiency of intratumoral
drug
uptake
in
vivo
using
quantitative
contrast-enhanced ultrasound (qCEUS) imaging of
the tumor vasculature, and (3) to explore molecular
changes in NB in response to sonopermeation
therapy, in order to better elucidate mechanisms of
drug uptake.
In the course of this study, we show that
contrast-enhanced focused ultrasound therapy can
effectively
increase
nanoparticle
uptake
in
experimental neuroblastoma by ~5-fold, and that
qCEUS imaging can function as an effective predictor
of sonopermeation efficiency in vivo. Specifically, our

8145
study results indicate that reperfusion rates (flow
rates following a short fragmentation US pulse) are
very sensitive to immediate changes in vascular
permeability induced by bubbles. Changes in
reperfusion rates immediately after sonopermeation
increased by ~2-fold when using tumor-free Matrigel
plug models, but decreased by ~2-fold when using
neuroblastoma tumor models. Changes in total
perfusion volume did not fluctuate significantly in
either Matrigel plugs or neuroblastoma xenografts
following
sonopermeation.
Although
overall
perfusion did not change significantly from pre- to
post-treatment, we show that initial tumor perfusion
can be a critical determinant of total chemotherapeutic
uptake. Our results indicate that liposomal
doxorubicin can effectively be delivered using
focused ultrasound and microbubbles without
damaging the integrity of blood vessels comprising
the tumoral vascular network, which is essential for
continued chemotherapeutic delivery to tumors.
We also demonstrate the biological effects of
sonopermeation in neuroblastoma xenografts at 30
min and 24 h post-treatment. We show that
ultrasound exposure with microbubbles causes
discontinuous pericyte coverage and distended blood
vessels, which likely leads to increased drug
permeability and slower blood flow observed using
qCEUS. Apoptotic effects of doxorubicin on tumor
cells are apparent 24 h after sonopermeation using
TUNEL staining, while no significant change in
apoptosis is observed with sonopermeation alone.
Our results suggest that anti-tumoral effects are
instigated by drug treatment rather than the
mechanical effects of microbubbles and ultrasound.
Lastly, a case study in which image-guided qCEUS
imaging was used to examine the effects of bubble
destruction in a liver tumor, using a protocol
analogous to the methodology used in neuroblastoma
xenografts, has also been included to demonstrate the
clinical feasibility of this strategy.
Together, this data serves as proof-of-principle
that ultrasound image-guided therapy can provide a
robust and rational approach to monitoring
sonopermeation in vivo, with potential for predicting
and controlling drug dosing in a clinical setting.

Materials and Methods
Preparation of Microbubbles
Microbubbles were formulated using a lipid film
composed of 14.34 mg of 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC, 790.16 MW) and 5.66 mg of
N-(methylpolyoxyethylene
oxycarbonyl)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine
(DSPEPEG2000, 2805.97 MW) (NOF Corporation, Tokyo,
http://www.thno.org
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Japan), dissolved in chloroform (Sigma-Aldrich, St.
Louis, MO). The lipid solution was evaporated for 48
h and then stored as a lipid film in a sealed
scintillation vial at -20 °C. On the day of intended use,
the 20 mg film was diluted to 2 mg/mL in a filtered
mixture of 10% propane-1,2-diol (propylene glycol,
76.1 FW) (v/v), 10% propane-1,2,3-triol (glycerol,
92.09 FW) (v/v), and 10× phosphate buffer saline
(PBS) diluted to 1× (Fisher Scientific, Waltham, MA).
The lipid solution was heated to 65 °C on an Isotemp
Heating Block and bath sonicated in a 1.9 L Ultrasonic
Bath Sonicator (Fisher Scientific, Waltham, MA) until
the lipid was completely suspended. Microbubbles
were generated using probe micro-tip sonication
(Branson 450 Ultrasonics Sonifier with microtip
attachment, Emerson, St. Louis, MO) at 70% power
under constant flushing with Decafluorobutane (PFB,
238 MW, FluoroMed LP, Round Rock, TX) for 10 s.
The amalgamated lipid suspension was brought
below the glass phase temperature and washed three
times in a 10 mL Luer tip syringe (BD, Franklin Lakes,
NJ) at 300 relative centrifugal force (RCF) for 3 min in
a Bucket Centrifuge Model 5804R (Eppendorf,
Hauppauge, NY) to concentrate and collect the
bubbles, until the infranatant appeared clear. The
microbubbles were characterized using a Multisizer
4e Coulter Counter (MS4, Beckman Coulter, Brea, CA)
to determine size distribution and concentration.

Liposome Formulation
A mock Doxil liposome was fabricated using a
lipid film containing 7.56 mg of DSPC, 2.69 mg of
cholesterol, and 2.44 mg of DSPE-PEG2000. The lipid
solution was evaporated for 48 h and then stored as a
lipid film in a sealed scintillation vial at -20 °C. On the
day of intended use, the 10 mg film was diluted to 8
mg/mL with filtered pH 7.5 PBS and heated to 65 °C
via bath sonication until the lipid became fully
suspended. For the purpose of fluorescence
microscopy, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine dye (DiD, 498.48 MW, 1 mM dilution,
Sigma-Aldrich, St. Louis, MO) was added to the
liposome solution at 2.1 µg per 1 mg of lipid and
sonicated an additional 10 min.

Matrigel Implantation
Optimization of image-guided drug delivery
was initially performed in highly controllable
Matrigel tumor models. Matrigel plugs are
well-established angiogenesis models that have been
extensively characterized [41,42]. Matrigel plugs are
formed by subcutaneous injection of a soluble
basement membrane extract derived from the
Engelbreth-Holm-Swarm tumor (Fisher Scientific,
Atlanta, GA). Subsequent to injection, host
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endothelial cells rapidly migrate into the plug, and
begin blood vessel formation. Blood vessel growth
occurs relatively uniformly between plugs and
without
the
complexities
and
type-specific
heterogeneity that typically occur with different
xenograft tumor models. Therefore, we reasoned
these could function as excellent models for studying
the effects of sonopermeation on perfusion kinetics in
neovasculature. Prior to injection, frozen Matrigel was
thawed overnight on ice. 12 µg human recombinant
basic fibroblast growth factor (bFGF, Stemgent,
Beltsville, MD) and 350 µg heparin were added to 10
mL Matrigel to stimulate blood vessel ingrowth. 1 mL
of Matrigel mix was loaded into chilled 1 mL BD
syringes using chilled 16-gauge needles. After
loading, the needle was replaced with a 27-gauge
needle and kept on ice until animals were prepared.
No exogenous cells (tumor or endothelial) were used
in Matrigel studies.
All animal experiments were approved by the
UT Dallas or University of Chicago IACUC. Female
CD-1 mice (Charles River, Wilmington, MA) were
anesthetized with 2-3% isoflurane (Vedco, St. Joseph,
MO) and restrained in the prone position. A shaved
and disinfected region above the left kidney received
1 mL of chilled Matrigel solution subcutaneously,
creating a spherical plug (1 mm3). At 14 days
post-injection, mice were imaged with MB contrast
agents to evaluate blood perfusion and tissues
harvested for processing.

Orthotopic NGP Tumor Model and
Implantation
NGP cells are MYC-N amplified [43], and thus
are a commonly used model for poor prognosis NB.
They share many features of clinical NB such as
histology, frequency, and location of metastatic
lesions when renally implanted [44], as was done in
nude athymic mice (Charles River, Wilmington, MA)
to generate tumor models for this study. Mice were
first anesthetized with inhalable isoflurane. After
being positioned in a sterile environment, the entire
right side of each mouse was cleaned with ethanol
and painted with Betadine. A 3-5 mm diagonal
incision was made with a scalpel blade in the
direction of the ribcage atop the kidney. The
underlying fascia was divided with scissors to expose
the mouse’s internal organs. The kidney was
identified and delivered from the abdominal cavity,
using forceps and a cotton-tipped applicator. A
27-gauge needle (of length 1.3 cm, BD Biosciences)
fitted to a syringe containing 100 μL of cell suspension
(1x106 NGP cells in Phosphate Buffered Saline,
Leibniz Institute DSMZ-GmbH, Braunschweig,
Germany) was inserted into the kidney and its
http://www.thno.org
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contents injected slowly. The kidney was then
returned to the abdominal cavity. The incision was
closed in layers with absorbable suture, followed by
staples to close the skin. Mice were monitored daily to
ensure complete recovery, and tumors were allowed
to grow for 5-6 weeks (1-2 g weight) before ultrasound
experiments were commenced.

3D Volume and Perfusion Imaging
3D imaging was performed by mounting a linear
15L8 transducer, equipped with the Acuson Sequoia
512 ultrasonography system (Siemens Medical
Solutions, Erlangen, Germany), on a stepper motor,
and sweeping it across the length of the tumor in 0.2
mm increments. Data was collected and subsequently
analyzed using custom LabVIEW software. The
resulting series of 2D section scans was combined in
ImageJ to capture volumetric measurements (B-mode)
and to map the vasculature in and around the tumor
(CPS mode). Non-linear contrast images were
acquired following a bolus injection of 5x107 MBs in a
total volume of 100 µL, administered via tail vein
catheterization.

Perfusion-Guided Monitoring of Drug Uptake
in Matrigel Plugs
Mice bearing Matrigel plugs were 3D imaged
prior to sonopermeation to assess the initial level of
perfusion; Matrigel plugs were utilized to mimic
tumors as they are a good model for angiogenesis. A
high dose of microbubbles (1x109 total MBs) was
combined either with 25 mg/kg L-DOX (Doxoves©,
FormuMax, Sunnyvale, CA) or FITC-Dextran (2 kDa,
5 mg/mL in PBS) and systemically introduced via tail
vein injection. Subcutaneous tumor-free Matrigel
plugs were sonopermeated with a handheld
therapeutic ultrasound machine (SoundCare Plus,
Austin, TX) at 0-3 W/cm2 (1 MHz, 10% duty cycle,
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alternating 5 seconds on and 5 seconds off) for 10 min.
30 min post-sonopermeation, the tumors were again
3D imaged to evaluate changes in the vasculature.
Finally, Matrigel, contralateral kidney, liver, and heart
tissue were excised 24 h after sonopermeation and ex
vivo analysis was performed (Figure 1).

Sonopermeation In vivo Using Focused
Ultrasound Application
A custom lens and cone system was developed
to elevate pressure in the focal zone (~ 2 MPa peak
negative pressure, Supplementary Figure 1) and was
affixed to the therapeutic ultrasound probe. A
commercial infusion pump (Kent Scientific,
Torrington, CT) was coupled to a custom 3D printed
rotating syringe platform (similar to Kaya et al [45]),
designed to evenly disperse the microbubbles in
solution, ensuring that sustained infusions occurred
at a fixed concentration throughout the duration of
microbubble administration (Figure 2A). Pre- and
post-sonopermeation
perfusion
kinetics
were
obtained in a single 10 min infusion: 1x109
microbubbles were combined with 100 µL of DiD
liposomes and brought up to a total volume of 500 µL
with sterile saline. Microbubbles flowed into the
tumor space at a constant rate of 50 µL/min and were
allowed to reach steady-state over a period of 5 min,
after which a flash-destruction pulse (MI = 1.9) was
applied to clear all bubbles from the imaging plane.
Microbubbles were then given 30 s to re-circulate,
following which tumors were sonopermeated (3
W/cm2) on/off five times for 5 s each. This procedure
was repeated for four cycles, interspersed by 30 s gaps
to permit replenishment. At the 10.5 min mark, the
tumor was hit with a final flash-destruction pulse
(Figure 2B).

Figure 1. Cartoon depiction of workflow for unfocused ultrasound experiments. Mice bearing tumor-free Matrigel plugs were imaged (15 MHz) in 2D and 3D prior to
sonopermeation to establish a baseline of tumor perfusion using a bolus of 5x107 MBs. Next, microbubbles and drug were systemically introduced via tail vein injection and
subcutaneous tumors were sonopermeated with a handheld therapeutic ultrasound transducer (1 MHz) using a high concentration of MBs (1x109 MBs in 500 µL). 30 min
post-sonopermeation, tumor-free Matrigel plugs were imaged again to assess changes in the vasculature. Finally, tissue was excised 24 h after sonopermeation and ex vivo analysis
was performed to quantify FITC-Dextran uptake.

http://www.thno.org
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Figure 2. Perfusion-guided sonopermeation of neuroblastoma tumor models using qCEUS imaging techniques to monitor vascular changes. (A) A rotating syringe pump was
used to administer constant infusions over long periods of time during sonopermeation experiments. (B) Screen captures from the clinical ultrasound scanner illustrate non-linear
2D imaging of a neuroblastoma tumor sonopermeated using 1x109 MBs. The selection of appropriate ROIs encompassing the sonopermeated focal zone (solid white line) and a
designated control region (dashed white line) at the periphery of the tumor has been indicated. The series of ultrasound images show contrast enhancement before
sonopermeation, followed by focused ultrasound triggered microbubble destruction in vivo during four sonopermeation treatment cycles, culminating in MB recovery within the
tumor space post-sonopermeation; the accompanying time-intensity curves (TICs) – corresponding to the “treated” and “untreated” ROIs – have been split into three matching
stages. (C) MB reperfusion after the initial (FD-1 = 300 s) and final (FD-2 = 630 s) flash-destruction pulses were fitted to an exponential model and the resultant curves were
compared to assess sonopermeation-mediated changes in perfusion kinetics.

As described by Wei et al [46], microbubble
reperfusion following flash-destruction is governed
by the exponential equation:
y = A (1 – e-βt)
Perfusion recovery curves generated from CPS
data were fit to this form in the LabVIEW software
and plotted on the same set of axes (Figure 2C).
Measures of the relative blood volume (RBV = A) and
the rate of reperfusion (RR = β) were extracted and
compared pre-treatment and post-treatment in the
sonopermeated region and an area outside the tumor
(designated as the internal “control region”) for each
mouse.

Tumor and Matrigel Excision
Mice were sacrificed 24 h post-sonopermeation
by exsanguination to remove drug remaining in
circulation. Prior to exsanguination, mice were
anesthetized using 5% isoflurane. After confirming
depth of anesthesia by toe pinch, animals were
exsanguinated by intracardiac perfusion of 1%
paraformaldehyde (for IHC of mice sonopermeated
without drug) or cold saline (for drug quantification).
This procedure was performed by inserting a syringe
with 20 mL of solution into the left ventricle and
cutting the right atrium prior to flushing out the
mouse’s
circulatory
system.
All
Matrigel
plugs/tumors were surgically excised for ex vivo
processing immediately after perfusion.

FITC Dextran Quantification in Matrigel Plugs
Drug uptake in Matrigel plugs was evaluated
using a procedure similar to a previously reported
study by Prewett et al [47]. Matrigel plugs were
removed and transferred to tubes containing 0.5 mL
of Dispase reagent (Becton Dickinson). Plugs were
incubated for 1 h at 37 °C and then stored overnight at
4 °C. The plugs were then tip sonicated using a
microtip sonicator (Branson) at 30% power until a
homogenous slurry was obtained. Sterile saline was
added to the tubes, which were then vortexed and
centrifuged at 2000 rpm for 5 min. The supernatant
was separated and the accumulated FITC-Dextran
was quantified by measuring the fluorescent
properties of the 2 kDa FITC (488/515 nm ex/em) on
a fluorescent microplate reader (Synergy H1 Biotek,
Boston, MA). A standard curve of known
FITC-Dextran concentrations was used to determine
total uptake in the Matrigel plugs after normalizing to
plug weight.

Doxorubicin Quantification in Matrigel Plugs
and NGP Tumors
Doxorubicin quantification used a similar
approach adopting a combination of two
methodologies by Bing et al [48] and Head et al [49].
Matrigel plugs or tumors were excised, weighed, and
snap frozen. Sections of tissue were weighed
(typically 50-100 mg) in 1.5 mL centrifuge tubes with a
http://www.thno.org
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cell lysis buffer (consisting of 0.25 M sucrose, 5 mM
Tris-HCl, 1 mM MgSO4, 1 mM CaCl2 pH 7.6) and 100
µL ceramic beads (MO BIO Laboratories, Carlsbad,
CA). The tubes were placed in a vial mixer
(Bristol-Meyers Squibb, New York, NY) for 45 s to
homogenize the tissue. In order to establish standards
of known doxorubicin measurements in homogenates
of Matrigel plugs and tumors, untreated tissue was
mixed with 2 µL of 10 mg/mL doxorubicin (Sigma
Aldrich) stock dissolved in DMSO and homogenized
as described above. Spiked homogenates were then
serially diluted with extraction buffer. The readings of
untreated plugs or tumor samples without
doxorubicin were considered zero. The untreated
samples with known concentrations of doxorubicin
were used in every plate, in order to accurately and
consistently quantify doxorubicin accumulation in
treated tissue. Untreated and treated homogenized
samples (200 µL) were placed in 1.5 mL
microcentrifuge tubes, with acidified isopropanol
solution: 100 µL of 10% (v/v) Triton X-100 (Sigma
Aldrich), 200 µL of water, and 1 mL of acidified
isopropanol (0.75 N HCl, Sigma Aldrich). Samples
were stored overnight at -20 ºC to extract the
doxorubicin. The next day, the microcentrifuge tubes
were warmed to room temperature, vial mixed for 45
s, centrifuged at 2,000 g for 15 min in a mini vortexer,
and stored at -80 ºC until analysis. The standard curve
generated by spiking tissue with known quantities of
doxorubicin was run side by side with experimental
samples to quantify uptake per gram of tumor or
Matrigel. Doxorubicin was also quantified in heart,
liver, and contralateral kidney tissue using the same
method.

Fluorescent Drug Uptake in NGP Tissue
Sections
For NGP tumors, whole tissue sections were
used to evaluate intratumoral accumulation of
doxorubicin and DiD tracer liposomes to assess
spatial distribution within the tumor. Tumors were
embedded in Tissue-Tek® optimum cutting
temperature
(O.C.T.)
compound
(Electron
Microscopy Services) over dry ice until frozen, then
stored at -80 ºC until cryosectioned. 5 µm thick
cryosections were visualized without mounting
media on a confocal microscope (Marianas or SP2,
Zeiss).

Histology and Immunohistochemistry
Some tumors and organs were fixed in 4%
paraformaldehyde overnight, dehydrated in 70%
ethanol and paraffin embedded. 5 µm sections were
used to stain for the apoptosis marker terminal
deoxynucleotidyl transferase dUTP nick end labeling
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(TUNEL, ApopTag, Millipore, following the
manufacturer’s instructions), the selective pericyte
marker alpha-smooth muscle actin (αSMA) [47]
(LabVision Actin, ThermoFisher Scientific), the
endothelial markers Endomucin (Santa Cruz
Biotechnology),
IsolectinB4-AlexaFluor488
(ThermoFisher Scientific), and hematoxylin and eosin.
Whole H&Es, αSMA, Endomucin, and TUNEL tissues
were scanned in a CRi Pannoramic Midi 20x Whole
Slide Scanner (3DHistech). Data and images were
analyzed using Pannoramic Viewer software
(3DHistech). DOX and DiD were quantified on fresh
frozen tumors stored in OCT and then cut into 5 µm
sections, using a Marianas Confocal Microscope
(Zeiss) at 561 nm laser (L-DOX) and 640 nm laser
(DiD) wavelengths. At least eight images at a 40x
magnification of three tumors per group were taken at
random by focusing on the DAPI channel.
Quantification was performed in ImageJ, using the
mean grey area of 16-bit images, normalized by total
DAPI area to account for variations in intratumoral
structures, such as a large blood vessel without tumor
cells. Figures were then processed in Adobe Illustrator
cc 2018 (Adobe). In order to measure vascular caliber
(blood vessel diameter), we used tumor sections
stained against a marker of the endothelium, the
innermost layer of cells in blood vessels, known as
Endomucin. NGP tumors immunostained against
Endomucin were scanned, and images analyzed using
the Pannoramic Viewer software (3DHISTECH).
Taking this endothelial marker as an indicator of the
vascular wall, we defined the vascular caliber as the
longest axis spanning the inside of Endomucin
stained endothelial cells, using the “Create Distance
Measurement Annotation” on Pannoramic Viewer
software. One hundred measurements of vessel
caliber were created from each tumor section in
randomized locations within each tumor, three
tumors were analyzed per group, and statistical
analysis performed in Prism (GraphPad) using a
Wilcoxon Signed Rank Test (Supplementary Figure 5).
Lectin- and αSMA-positive cells were quantified from
fluorescent images taken at 10x magnification on an
Axioscop2 (Zeiss), and using the threshold tool in
ImageJ. Statistical analysis was performed with
Student’s T-test in Excel (Microsoft). Four pictures per
tumor section for at least three sections were taken
from fresh frozen samples, excluding kidney areas
and non-viable tumor areas.

Sonopermeation in Human Patients
Human imaging data was collected as part of an
ongoing clinical trial using sonopermeation for
sensitizing
hepatocellular
carcinoma
to
radioembolization therapy (NCT #03199274). This
http://www.thno.org
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study is approved by the Food and Drug
Administration (IND #126,768) and the Institutional
Review Board of Thomas Jefferson University. All
patients provided informed consent prior to
participation. Imaging was performed using an S3000
scanner with a 6C1 probe and flash-replenishment
and non-linear imaging packages (Siemens
Healthineers, Mountain View, CA) by a sonographer
possessing over ten years of experience.
For contrast agent infusions, 5 mL of activated
Optison (GE Healthcare) was suspended in 50 mL of
saline and infused through an 18- to 20-gauge
angiocatheter placed in a peripheral arm vein at a rate
of 120 mL/h. The tumor midline was first imaged
using Cadence Pulse Sequencing (MI = 0.06) for at
least 45 s until complete enhancement of the tumor
and adjacent liver was observed. Following complete
enhancement, the patient was asked to temporarily
halt respiration. Sonopermeation was performed
using a 4 s destructive pulse from the imaging
transducer (MI = 1.13 at 1.5 MHz, transmitting 2.3 µs
pulses at a pulse repetition frequency of
approximately 100 Hz), which is applied to all
microbubbles in the field of view. Following
sonopermeation, Optison reperfusion was imaged at
the tumor midline for at least 10 s. This
flash-replenishment sequence was repeated for at
least 5 cycles at the tumor midline after which full
intratumoral microbubble destruction was obtained
by manually sweeping through the tumor during the
4 s destructive sequences for the remainder of the
infusion. Following sonopermeation, patients were
monitored for 30 min and data extracted in DICOM
format for off-line processing.

Results
Sonopermeation Using Unfocused Ultrasound
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Does Not Increase Doxorubicin Uptake in
Matrigel Plugs
Image-guided studies were performed by
delivering 2 kDa FITC-Dextran molecules to
tumor-free Matrigel plugs to test whether an
(unfocused) commercial therapeutic ultrasound
system can improve small molecule uptake. We
applied 0 to 3 W/cm2 ultrasound intensities (which
corresponded to 0-0.6 MPa PnP, Supplementary
Figure 1). In these studies, 2D and 3D contrast
enhanced ultrasound (CEUS) imaging was performed
immediately before and 30 min after sonopermeation
therapy to assess changes in overall perfusion and
perfusion kinetics (Figure 3A-B). We did not detect
significant changes in perfusion volume in the
Matrigel plugs using the unfocused system (Figure
3A). Conversely, there was a statistically significant
increase in the rate of reperfusion after unfocused
sonopermeation at 2 and 3 W/cm2 (Figure 3B, red vs.
green line).
Next, we further characterized the effects of
unfocused ultrasound on perfusion and drug uptake
using Matrigel plugs. 3D contrast enhancement in the
Matrigel plugs did not show significant changes in the
relative
blood
volume
(RBV)
following
sonopermeation therapy at any intensity level (Figure
4A). However, reperfusion rates measured using
destruction-replenishment imaging showed a
significant increase in reperfusion velocity with
increasing ultrasound power (Figure 4B). While there
is a linear increase in the rate of reperfusion with
increasing ultrasound pressure, only ultrasound
intensities of 2 W/cm2 and 3 W/cm2 had statistical
increases in reperfusion rates above baseline (Figure
4B, 0.03 and 0.04 s-1 respectively, p<0.05).
Interestingly, the increase in reperfusion rate
correlated with small-molecule FITC-Dextran uptake,

Figure 3. (A) Examples of 3D reconstructions of Matrigel plugs generated from interpolating a series 2D non-linear contrast images taken pre- and post-unfocused
sonopermeation reveal no overall changes in relative blood volume or level of perfusion. (B) Examples of 2D flash-destruction imaging performed before (green) and after (red)
unfocused sonopermeation show an increase (p<0.05) in the rate of microbubble reperfusion in Matrigel plug models. * Indicates statistical significance in the difference between
pre- and post-sonopermeation rates as compared to untreated Matrigel plugs.
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Figure 4. Effect of unfocused sonopermeation on tumor perfusion and drug uptake. Mice assigned to the untreated group received neither microbubbles nor
FITC-Dextran/DOX nor ultrasound, whereas the 0 W/cm2 group received microbubbles co-injected with FITC-Dextran/DOX without ultrasound. (A) Percent change in the
relative blood volume before and 30 min post-sonopermeation from 3D qCEUS. (B) Change in reperfusion rates before and after sonopermeation. (C) Small molecule (2 kDa)
FITC-Dextran uptake in Matrigel plugs 24 h post-sonopermeation. (D) Doxorubicin uptake delivered using liposomal L-DOX 24 h post-sonopermeation. Ultrasound intensities
from 0-3 W/cm2 correspond to 0-0.6 MPa PnP. N = 4-5 mice per group. * Indicates p<0.05 compared to the untreated group.

which showed recovery of 24.5 and 33.3 µg
FITC-Dextran per gram of Matrigel tissue at 2 W/cm2
and 3 W/cm2 respectively (Figure 4C, p<0.05).
After demonstrating increased FITC-Dextran
delivery to Matrigel plugs, the methodology was
repeated using liposomal doxorubicin (L-DOX).
Despite increased FITC-Dextran uptake, there were
no significant changes in levels of doxorubicin in
excised Matrigel plugs following the same unfocused
sonopermeation experiments (Figure 4D). We
rationalized that this is likely due to the size of the
L-DOX molecules (~80 nm), which would not
extravasate as effectively as free drug in circulation. In
the next section, we detail our approach for
improving sonopermeation efficiency of liposomes
using focused ultrasound. In all subsequent
experiments, only uptake of large molecule L-DOX or
liposomes was investigated.

Sonopermeation Using Focused Ultrasound
Increases Liposome and Doxorubicin Uptake
in Matrigel Plugs
In order to achieve higher levels of ultrasound

application that would facilitate larger molecule
uptake in tumors, we utilized a custom focusing lens
attached to the therapeutic ultrasound system to
generate pressures up to 2.35 MPa (Supplementary
Figure 1) within the tumor space. We then tested
whether focused ultrasound could increase larger
particle (80 nm liposomes) uptake in Matrigel plugs.
In order to facilitate ex vivo detection, the liposomes
were labeled by incorporating DiD in the bilayer.
Focused ultrasound was applied at a maximal
pressure of 2 MPa using either 108 or 109 total MBs
together with liposomes diluted in PBS. Similar to
unfocused ultrasound (Figure 4A), total perfusion in
the Matrigel plugs remained unchanged before and
after sonopermeation (Figure 5A), but reperfusion
rates increased significantly in the focal region where
ultrasound was applied (Figure 5B). Liposomal
uptake was detected in Matrigel plug cross sections
by DiD fluorescence (Figure 5C, purple) and greater
accumulation was qualitatively observed in the
sonopermeated tumors as compared to the untreated
negative control tumors (Figure 5C, middle and right
panel vs. left panel).
http://www.thno.org
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Figure 5. Evaluation of focused ultrasound treatment on qCEUS parameters and DiD Liposome uptake in Matrigel plugs. (A) Changes in RBV from baseline (before
sonopermeation) using two different concentrations of MBs co-injected with DiD labeled liposomes. (B) Change in reperfusion rate after sonopermeation using the same tumors.
Values were calculated by selecting an ROI in the sonopermeated focal zone and normalizing against non-sonopermeated control ROIs outside of the tumor area, as described
in Figure 2. A paired Student’s T-test was performed with N = 3 mice per group. * Indicates p<0.05 and ** indicates p<0.01 and reflect that these groups are significantly different
than the baseline value. (C) Effect of MB concentration on nanoparticle accumulation. Sections of sonopermeated and non-sonopermeated Matrigel plugs were visualized on a
whole slide scanner (Olympus VS120 Virtual Slide Microscope).

Furthermore, ex vivo analysis of Matrigel plugs
showed increased levels of RBC extravasation at
elevated pressures of up to 2 MPa using focused
ultrasound, potentially indicative of egress of 4-7 μm
diameter particles (murine erythrocytes are 4-7 μm;
Supplementary Figure 3, arrows).
Next, we asked whether sonopermeation with
focused ultrasound would increase L-DOX uptake in
Matrigel
plugs.
When
sonopermeated
and
non-sonopermeated mice were compared, a 5-fold
increase in L-DOX accumulation was observed in
Matrigel plugs accompanied by no statistically
significant change in any of the other organs analyzed
(Figure 6, p<0.05). Histological analysis confirmed
this tissue extraction data, wherein greater liposomal
uptake was noted in Matrigel tumors alone (Figure

5C, data for heart, liver and kidney not shown). While
only one L-DOX concentration was tested in this
study, future studies that examine a lower range of
concentrations are warranted to demonstrate that
lower dosages can achieve an equivalent therapeutic
response to standard L-DOX treatments.

Initial Degree of Vascularity Influences the
Extent to Which Sonopermeation Enhances
Doxorubicin Uptake
Since no change in relative blood volume was
distinguishable pre- and post-sonopermeation
(Figures 3A & 5A), we addressed the question of
whether perfusion volume does, in fact, affect
sonopermeation efficiency. Given that the number
and size of blood vessels will increase over time in a
http://www.thno.org
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Matrigel plug, we evaluated whether the number of
days post-implantation, and thus vascularization
levels, affect DOX uptake. We found that vascularity
alone does not facilitate DOX uptake (Figure 7A,
white circles). However, when sonopermeation is
combined with greater perfusion volume, there is a
linear increase in L-DOX uptake (Figure 7A, black
diamonds), implying that the level of tumor perfusion
may serve as a good predictor of drug accumulation.
Increases in vascularity were confirmed in
sonopermeated mice with qCEUS imaging (Figure 7B)
by using the relative blood volume (RBV, measured in
arbitrary pixel units) and normalizing to tumor
volume (TV, mm3). Example images of perfusion
within tumor-free Matrigel plugs at varying time
points post-implantation are shown in Figure 7C.
Matrigel plug sizes tend to shrink over time as they
are reabsorbed in the body while blood vessel growth
continues to increase with time, likely leading to more
efficient doxorubicin uptake per unit volume.
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Figure 6. Focused ultrasound increases drug uptake in Matrigel plugs. A 5-fold
increase in L-DOX accumulation was achieved in Matrigel plugs sonopermeated with
a high dosage of microbubbles (109 MBs in 500 µL) as compared to their
non-sonopermeated counterparts, accompanied by no statistically significant
difference in other organs, suggesting that sonopermeation drove more L-DOX
selectively into the tumor without simultaneously increasing uptake in the heart, all
without increasing the dosage of administration. N = 5 mice per group. * Indicates
p<0.05.

Figure 7. Effect of Matrigel age and perfusion on doxorubicin uptake. (A) Sonopermeation efficiency increases with Matrigel plug maturity (black diamonds). No effect of Matrigel
age on doxorubicin uptake is observed without sonopermeation (white circles). (B) Normalized relative blood volume (RBV) measurements from qCEUS imaging of Matrigel
plugs show a similar increasing trend in doxorubicin uptake with increased perfusion. (C) Examples of 3D qCEUS measurements of tumor volume (TV) and perfusion (RBV) from
four sonopermeated Matrigel plugs. Matrigel plugs are reabsorbed over time causing a decrease in TV while RBV increases, thus enhancing the effectiveness of sonopermeation.
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Figure 8. Effect of sonopermeation alone (no L-DOX) on qCEUS parameters and NGP tumoral vasculature 30 min post-treatment. (A) Change in RBV after sonopermeation
within the sonopermeated tumor compared to unsonopermeated control region outside the tumor (see Figure 2 for ROI selection). (B) Change in RR after sonopermeation
using the same ROIs. (C-G) Ex vivo analysis of NGP tumors harvested 30 min after sonopermeation alone (right column) or following no treatment (Untreated Control, left
column). (C) Hematoxylin (blue) and eosin (pink-red) (top and middle rows) with remaining kidney (KD, light pink) highlighted by the dotted black line (top row) revealed no
change in cell death as a result of sonopermeation (homogeneous blue staining). (D) 20x magnification (middle row) of an area away from normal kidney (yellow dotted square
in top row) shows increased blood vessel diameter (black arrows) in the treated tumors compared to untreated controls. (E) Sonopermeation led to discontinuous pericyte
coverage (black arrowheads) illustrated by interrupted alpha-smooth muscle actin immunostain (αSMA, third row). (F) TUNEL staining (red, white arrows) was used to detect
cell death, which was minimally observed in untreated or sonopermeation alone mice. (G) Sonopermeation alone increases blood vessel dilation. Lumens (“L”) were measured
using Pannoramic Viewer; the longest distance between Endomucin immunostained cells was measured, and over 100 measurements of randomized locations per tissue were
analyzed (see Supplementary Figure 5). N = 3 mice per group.

Sonopermeation Increases Vascular
Permeability in Neuroblastoma
Next, we turned our focus from Matrigel model
tumors to orthotopic human NB xenografts. Similar to
the Matrigel model, quantification of changes in
relative blood volume divulged no statistically
significant change in the level of perfusion between
the non-sonopermeated and sonopermeated regions
in xenografts (Figure 8A). However, a significant
decrease (79±23%, p<0.01) in reperfusion rate was

observed in the sonopermeated region compared to
the untreated control region (Figure 8B). In order to
further characterize the effects of sonopermeation
alone, we analyzed tumor histology 30 min after
treatment. Hematoxylin and eosin (H&E) revealed
sonopermeated tumor overall histology and
architecture were comparable to that of untreated
controls (Figure 8C). The lighter, pink areas
demarcate remnant kidney tissue (Figure 8C, first row
“KD”), unaltered by sonopermeation, and blue
staining overall indicates no loss of tumor viability or
http://www.thno.org

Theranostics 2020, Vol. 10, Issue 18
architectural changes (Figure 8C). Upon higher
magnification, we found that sonopermeation did
induce vascular dilation versus untreated controls
(Figure 8D, black arrows). In order to confirm
whether sonopermeation affected the vascular lumen,
we immunostained tumors against the endothelial
marker Endomucin. We then measured the longest
axis between Endomucin-stained endothelial cells on
opposing vessel walls, and validated that
sonopermeation significantly increased vascular
dilation (Figure 8G; median diameter of 15.9 µM for
controls compared to 21.5 µM for sonopermeation,
RankSum 653 in controls vs. 3003 in sonopermeation,
p<0.0001). Pericytes contribute to capillary diameter
and vascular permeability through their direct contact
with endothelial cells; we interrogated the effect of
sonopermeation on pericytes using the marker αSMA
(reviewed by Bergers and Song [50]), used to identify
mature pericytes in experimental neuroblastoma [51].
Immunostaining of sonopermeated tumors revealed
discontinuous pericyte coverage of endothelial cells,
consistent with increased vascular dilation and
permeability (Figure 8E, black arrowheads). In order
to determine whether changes in pericyte
morphology were due to pericyte death, we analyzed
the apoptosis marker TUNEL. TUNEL staining
revealed no change in pericyte apoptosis in the
sonopermeated tumors (Figure 8F, white arrows), or
in the number of TUNEL positive αSMA cells (data
not shown). Finally, we observed an increase in
extravasated red blood cells adjacent to discontinuous
pericytes as a result of sonopermeation (Figure 8E,
8G). Together, this data suggests that sonopermeation
itself (at the prescribed settings in this study) can
increase vascular permeability in NGP tumors
without damaging the vasculature.

Sonopermeation Increases Doxorubicin
Uptake in Orthotopic NB Xenograft Tumors
and Increases Tumor Apoptosis
NGP tumors receiving L-DOX and DiD
liposomes without sonopermeation had 231±33%
increase in L-DOX fluorescent intensity compared to
untreated ones (Figure 9B, p<0.05). DiD signal,
however, was barely detectable in this group, only
127±96% of the untreated control (Figure 9C, p=ns). In
contrast, sonopermeated tumors had 476±89% L-DOX
compared to untreated controls and 204±38% more
L-DOX than non-sonopermeated mice (Figure 9B,
p<0.01); we found L-DOX to accumulate in the nuclei
of tumor cells that had undergone sonopermeation
(Figure 9A, top right panel, green). In parallel with
this finding, sonopermeated tumor DiD fluorescence
was 514±232% of untreated controls (Figure 9C,
p=0.04) and 404±183% of non-sonopermeated mice
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(Figure 9C, p=0.056); mice treated with L-DOX and
DiD liposomes without sonopermeation had no
difference in DiD compared to untreated controls
(Figure 9C, p=ns). This data suggests increased
vascular permeability as a result of sonopermeation.
Next, we quantified the vascular lumen 24 h
post-sonopermeation by measuring the intervening
length between cells lining the vasculature on either
side of the vessel, using the Endomucin marker
(Figure 9A, bottom row, brown color). Indeed, the
vascular caliber was significantly larger in
sonopermeated tumors than in untreated controls
(median diameter of 15.9 µM for controls versus 29.8
µM for sonopermeation; Rank Sum 653 vs. 4072
respectively, p<0.0001), demonstrating that the
vascular
dilation
observed
30
min
post-sonopermeation (Figure 8G) not only persisted
but increased 24 h later (p<0.01). Meanwhile, lumens
of tumors receiving L-DOX without sonopermeation
were not different from untreated controls (Figure 9A,
bottom row, middle panel).
Next, we analyzed the effects of enhanced,
sonopermeation-induced L-DOX delivery to tumors
at the cellular level. Histological analysis revealed
large clusters of TUNEL positive tumor cells in
sonopermeated tumors (Figure 9A, middle row, white
dots, yellow arrows). Although L-DOX alone
increased the number of apoptotic tumor cells
compared to untreated controls, the pattern of
apoptotic cells remains scattered throughout the
tissue, suggesting that many tumor cells escaped
L-DOX treatment in the absence of sonopermeation.
Sonopermeation, on the other hand, revealed large
areas of tumor cell death owing to the effects of DOX
after a single treatment, as is evident in this example
(Figure 9A, middle right panel, yellow arrows). In
sum, our data suggests that sonopermeation increases
tumoral DOX uptake by increasing vascular
permeability.

Sonopermeation in Clinical Testing
Here, we present the results from a single patient
sonopermeation experiment (Figure 10). Similar to
NGP xenograft studies which show slower
reperfusion following 4 cycles of sonopermeation,
qCEUS also shows a slight decrease in relative blood
volume (RBV) following sonopermeation (Figure
10C); however the UCA replenishment times in this
study were much shorter than what was used for
NGP xenograft studies, thus full reperfusion may not
be observed. Although the procedures and results
between human and animal testing were similar,
there are several key differences between the
experiments noted in the discussion section.
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Figure 9. Evaluating drug uptake and vasculature changes in NGP tumors 24 h after sonopermeation. (A) Ex vivo evaluation of NGP tumors using histology and immunostaining
to evaluate levels of doxorubicin and liposomal DiD uptake, cell death (TUNEL), lectin, αSMA, and Endomucin (lumen). Untreated tumors (left column) were compared with
tumors given L-DOX and DiD liposomes only (no sonopermeation, middle column), and sonopermeated tumors (right column). Low magnification of the apoptosis marker
TUNEL reveals that sonopermeation with L-DOX led to large clusters of apoptotic tumor cells at 24 h (second row, white dots, yellow arrows) although no observable changes
in blood vessel (lectin) or pericyte coverage (αSMA) were observed (third row). Sonopermeation caused enlargement of vascular lumens (marked L) in the presence of L-DOX:
lumens were measured using Pannoramic Viewer, the longest distance separating Endomucin immunostained cells was measured, and over 100 measurements of randomized
locations per tissue were analyzed (see Supplementary Figure 5). (B) Quantification of doxorubicin in NGP tumors calculated by average fluorescent intensity within the tumors.
Image intensities are ~2 and 5-fold higher for L-DOX/DiD only and sonopermeated tumors with L-DOX/DiD respectively. Untreated controls show a small level of background
signal due to tissue autofluorescence. (C) Comparison of liposome uptake in NGP tumors using average DiD fluorescent intensity. Infusion of L-DOX without sonopermeation
did not alter DiD uptake in tumors compared to the untreated controls. Sonopermeation increased DiD presence in the tumors approximately 5-fold. (D) Quantification from
low magnification (10x) images reveals no significant changes in endothelial marker lectin or pericyte marker αSMA. N = 3 mice per group. * Indicates p<0.05 and ** indicates
p<0.01.

Discussion
The clinical impact of contrast-enhanced
ultrasound imaging is growing rapidly, yet the
application of qCEUS imaging in drug therapies
remains limited. In this study, we combine qCEUS
imaging
with
a
technique
known
as
“sonopermeation” (also called “sonoporation” or
“sonopermeabilization”) to facilitate drug uptake in
an experimental model of neuroblastoma and monitor
tumor response to sonopermeation therapy in vivo.
Sonopermeation using UCAs can effectively increase
vascular permeability, thus eliminating dependence
on the endogenous tumor vasculature. However,

methods of monitoring and controlling vascular
permeability in vivo are lacking. The overall goal of
this study was to demonstrate that sonopermeation is
a rational approach to improving the efficacy of
liposomal doxorubicin therapy in neuroblastoma and
that contrast-enhanced imaging can be used to
monitor the effects of sonopermeation and accurately
assess liposomal drug uptake in vivo. Over the course
of this study, we developed a unique methodology
with clinical potential for simultaneously monitoring
and treating neuroblastoma (and other solid tumors)
using sonopermeation therapy, capitalizing on 2D
and 3D qCEUS imaging.

http://www.thno.org

Theranostics 2020, Vol. 10, Issue 18

8157

Figure 10. Sonopermeation in a clinical setting. The above images constitute an example of how image-guided sonopermeation can be accomplished in patients using a single
continuous infusion of ultrasound contrast agents. (A) Summary of methodology for performing imaging and flash-destruction cycles followed by full destruction of contrast
agents. (B) Representative images of contrast agent infusion, contrast agent destruction, and reflow in hepatocellular carcinoma (outlined in white). (C) Mean pixel intensities
immediately following the first (green) and last (red) flash destruction pulse.

Monitoring Sonopermeation and Evaluating
Drug Uptake in Matrigel Plug Models
Our initial experiments were performed in
Matrigel plug models in order to evaluate small
molecule drug uptake (2 kDa) and liposomal
doxorubicin uptake using relatively low-ultrasound
intensities (<0.6 MPa). Our results demonstrated that
sonopermeation did in fact promote small molecule
delivery using 2 kDa FITC-Dextrans without
noticeable changes in total perfusion (measured by 3D
qCEUS imaging). Interestingly, we observed that
reperfusion rates tend to increase following
sonopermeation (94±57% with 108 MBs; 47±9% with
109 MBs; Figure 5B) and correlate with increasing
drug uptake. The exact mechanism for improved
perfusion rates (without changes in overall perfusion)
in the Matrigel plugs following sonopermeation is
unknown but may be attributed to pruning of the
microvasculature and redirecting of blood to larger
vessels more visible by ultrasound.
One of the key findings from our Matrigel study
was that low-intensity ultrasound was able to
facilitate small molecule drug delivery to Matrigel
plugs in vivo, but not liposomal drug carriers (Figure
4C-D). We used high dosage chemotherapy (25
mg/kg doxorubicin) to facilitate visualization and
detection of accumulated doxorubicin in these
studies, however no increase in doxorubicin uptake
could be observed with increasing ultrasound
intensity. We rationalized that the encapsulation of
doxorubicin into liposomes, which increases the

overall drug size to ~80nm, likely requires higher
levels of permeabilization to effectively extravasate
into tissue, although other factors such as doxorubicin
low quantum efficiency may also have resulted in
poor detection in Matrigel plugs. In order to improve
delivery, we sought to increase the ultrasound
intensity applied during sonopermeation. The
maximum output of the therapeutic transducer was
~0.6 MPa. To achieve higher ultrasound intensities,
we developed an acrylic focusing lens that attached to
the soundhead of the therapeutic ultrasound system
(Supplementary Figure 1A). Using our focusing lens,
we could apply higher amplitudes of pressure (up to 2
MPa) at the focus to the Matrigel plugs while imaging
concurrently with a clinical scanner. Utilizing
ultrasound as a guide to position the focus, we were
able to demonstrate significantly enhanced levels of
liposome uptake in the Matrigel plugs, using
fluorescence microscopy of liposomes in sections of
Matrigel plugs (Figure 5C). At our maximum power
setting and high dosage of bubbles (1x109 bubbles in
500 µL), the highest level of liposome delivery was
observed without significant change in total perfusion
following sonopermeation therapy (Figure 5A). This
enhancement in liposomal uptake with increasing
microbubble concentration is believed to be a
consequence of higher degrees of vascular
permeabilization. In Matrigel plugs, injections of both
109 and 108 MBs show increases in reperfusion rates
(RR) after sonopermeation, however no significant
difference between these two concentrations was
http://www.thno.org
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observed. We attribute this to overall poor perfusion
of Matrigel tumors which likely decreases sensitivity
and increases variability in qCEUS imaging at lower
MB concentrations. Since the change in RR was
statistically significant at both microbubble
concentrations, while no significant change in RBV
was detected, we concluded that RR is a more
sensitive measure of sonopermeation effect. It may be
possible to improve accuracy using the area under the
curve (AUC), which accounts for both RR and RBV
terms in a single metric. This strategy has been used
by similar groups [52] and will be pursued in future
studies involving NGP tumors.
We then demonstrated that efficient L-DOX
delivery could be attained using our focused
ultrasound system. Doxorubicin measurements were
taken in excised Matrigel plugs, liver, contralateral
kidney, and heart tissue. Our results disclosed nearly
a 5-fold increase in doxorubicin uptake in Matrigel
plugs
using
focused
ultrasound
mediated
sonopermeation (Figure 6), with no change in uptake
in the heart. Therefore, it stands to reason that lower
dosages could be applied to reduce overall
cardiotoxicity while simultaneously improving
intratumoral drug uptake.

Monitoring Sonopermeation and Evaluating
Doxorubicin Uptake in Neuroblastoma Models
Recognizing the limitations of the Matrigel plug
model, the next phase of our project aimed to evaluate
whether qCEUS imaging could effectively monitor
sonopermeation in a highly relevant and
well-characterized
tumor
model
of
human
neuroblastoma. Similar to our previous results, TIC
analysis illustrated that sonopermeated sections of NB
tumors did not experience an overall decrease in their
level of perfusion as compared to non-sonopermeated
sections of tissue lying outside the tumor boundary
(Figure 8A). This finding is inconsistent with the work
of Burke et al [52] who reported significantly reduced
perfusion following 60 min of sonopermeation
therapy using an order of 106 MBs at four different
low duty cycle US pulsing schemes. Rather than
relying on a tethered or co-injected chemotherapeutic
agent to bring about anti-tumor effects, this group
activated the tumor apoptotic pathway by provoking
microvascular damage using microbubble cavitation.
They reasoned that mechanical ablation due to
ultrasonic microbubble destruction leads to reduced
blood flow, which in turn diminishes tissue
oxygenation and nutrient delivery, ultimately
inhibiting tumor growth and lowering the number of
viable tumor cells.
Identifying changes in tumor vasculature during
sonopermeation is imperative, as blood vessels are the
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route of systemic chemotherapeutic delivery. Our
results are particularly important as we can
demonstrate that permeabilization of the vasculature
is occurring without significant disruption of blood
flow, which is crucial for increasing intratumoral drug
penetration. We expect that increased levels of
ultrasound exposure would eventually result in
microvessel destruction or thermal ablation of tissue
(which could also be measured by qCEUS imaging),
but did not observe localized heating or tissue
damage
under
the
conditions
we
tested
(Supplementary Figure 2).
Similar to earlier findings in Matrigel plug
models, reperfusion kinetics of ultrasound contrast
agents following flash destruction appeared to be a far
more sensitive method of monitoring the effects of
sonopermeation. However, contrary to our earlier
findings, we observed a significant decrease in the
rate of microbubble reperfusion (instead of increase)
in sonopermeated tissue (Figure 8B, p<0.01)
compared with unsonopermeated control tissue. This
result, taken together with the evidence showing no
change in relative blood volume of sonopermeated
tumors (Figure 8A), indicates that vascular
permeabilization was achieved without inducing
blood vessel damage or destruction. We conjecture
that the decrease in the rate of reperfusion is a direct
result of increased hematocrit in the wholly intact
blood vessels – that is, microbubble destruction
effectively permeabilizes the vascular endothelium,
causing plasma to leak out, thus raising viscosity
within the lumen of the vessels. This in turn produces
higher resistance to microbubble flow which is
reflected in the qCEUS-derived time-intensity curve
(TIC). To explore this phenomenon, we performed
photoacoustic imaging to measure hemoglobin
content within the tumor, before and after
sonopermeation (Supplementary Figure 4). As
hemoglobin is readily detectable and functions as an
effective endogenous scatterer [53], hemoglobin was
treated as a surrogate for hematocrit. Our preliminary
results show an increase in hemoglobin content
within
the
tumor
immediately
following
sonopermeation, supporting the hypothesis that
increases in hematocrit correlate with the observed
increase in vascular permeability and improved drug
uptake. Therefore, the biophysical effect that
sonopermeation bears on microbubble perfusion
kinetics – it appears to increase the fraction of red
blood cells within vessels contained in the treated area
– renders it an effective predictor of intratumoral drug
uptake. No difference in oxygenated versus
deoxygenated hemoglobin was observed. While this
was only a single experiment, a recent report by
Schultz et al [54] similarly demonstrated an increase in
http://www.thno.org
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hemoglobin content in sonopermeated tumors using
an analogous protocol, supporting our preliminary
neuroblastoma data.
To establish a link between drug uptake and
sonopermeation
kinetics
in
vivo,
L-DOX
accumulation, changes in tissue morphology, and
apoptotic biomarkers were evaluated. As depicted in
Figure 9B, sonopermeation resulted in a 2.3-fold
increase in L-DOX uptake in NB xenografts as
compared to mice that were infused with
microbubbles
and
L-DOX
without
focused
ultrasound, and a 4.8-fold increase in uptake
compared with untreated controls (Figure 9B). A
decrease in the density of blood vessels was not
observed in the sonopermeation group, ascertained
by lectin staining (Figure 9A, middle row). This
constitutes a critical finding as sonopermeation is
intended to drive increased concentrations of drug
into the tumor without triggering vascular collapse.
Since therapeutic agents utilize the vasculature as a
physical route to reach their target site, inflicting
irreversible damage on the vasculature (endothelium
and/or pericytes) would be detrimental to the goal of
depositing large drug payloads into the tumor space,
especially if repeated deliveries are to be attempted as
required by most chemotherapy regimens. With this
objective in mind, longitudinal studies investigating
whether
vascular
changes
associated
with
sonopermeation result in long-term remodeling
(beyond 24 h) are still needed. In this particular body
of work, we elected to only perform qCEUS during or
immediately after sonopermeation and to evaluate
changes in vasculature at 30 min and 24 h using ex
vivo analysis; however, qCEUS imaging at extended
time points in subsequent studies would more fully
expound the tumor response to the increased
doxorubicin payload.
We also sought to determine whether
ultrasound-triggered
microbubble
destruction
induces apoptosis by itself, that is, in the absence of
L-DOX. H&E stained sections of sonopermeated
tumors exhibited no changes in architecture or
apoptosis (Figure 8F) immediately following
sonopermeation, but immunostaining of the pericyte
marker αSMA did reveal discontinuous coverage of
pericytes encircling the vascular endothelium (Figure
8E). These changes in pericyte morphology suggest a
mechanism for increased vascular permeability:
loosening of interendothelial junctions, allowing
greater extravasation. Future studies will address the
longevity of these effects and explicate whether or not
tight junctions are restored within 24 h.

Broader Applications in a Clinical Setting
While

the

focus

of

this

study

was

on

neuroblastoma, we believe that the techniques
outlined can have broader applications in a clinical
setting for perfusion-guided drug therapies in a wide
range of cancers. Here, we present a single case study
from an ongoing clinical trial where sonopermeation
was performed using simultaneous imaging and
therapy with a protocol resembling that described in
this paper. The procedure for sonopermeation can be
found in the methods section and is summarized in
Figure 10A, along with quantitative flash-destruction
imaging (Figure 10B) and results (Figure 10C). It is
important to note some of the key differences, which
include microbubble concentration, microbubble type,
and ultrasound application, due to stringent FDA
regulations. Despite barriers in comparing directly
between animal and human testing, this data serves
as proof-of-principle that the strategy used in this
paper can have direct clinical impact.
There are several challenges that still need to be
overcome
for
human
testing,
including
implementation of 3D imaging with motion correction
to reduce variability in qCEUS imaging, and analysis
of linearized data instead of logarithmically
compressed video images. Importantly, real-time
feedback to quantify reperfusion rates on-the-fly
would be highly beneficial for evaluating
sonopermeation
efficiency
during
treatment.
Additionally, more work needs to be done to correlate
the qCEUS imaging parameters with long-term tumor
response to therapy and overall survival.

Conclusion
Quantitative contrast-enhanced imaging is
attracting increasing interest, as UCAs are being
employed for both diagnostic imaging as well as
therapy. The applications of qCEUS imaging have the
unique and inherent capacity to offer real-time
assessment of therapeutic effectiveness. Monitoring
tissue permeability of a drug, as well as controlling
drug uptake with qCEUS, may dramatically improve
the clinical outcomes of therapeutic interventions. As
utilization of qCEUS imaging continues to advance in
clinical settings, the techniques proposed here could
become increasingly valuable, leveraging the growing
variety of nanoparticle drug therapies aimed at
varying tumor types in combination with emerging
ultrasound imaging technologies.

Abbreviations
αSMA: alpha smooth muscle actin; BBB: blood
brain barrier; CEUS: contrast enhanced ultrasound;
CPS: contrast pulse sequencing; DiD: 1,1′-dioctadecyl3,3,3′,3′-tetramethylindodicarbocyanine dye; EPR:
enhanced permeability and retention; FD: flashdestruction; FITC: fluorescein isothiocyanate; FUS:
http://www.thno.org

Theranostics 2020, Vol. 10, Issue 18
focused ultrasound; Hb: hemoglobin; IGDD: imageguided drug delivery; IHC: immunohistochemistry;
L-DOX: liposomal doxorubicin; MB: microbubble; NB:
neuroblastoma; PA: photoacoustic; PFB: perfluorobutane; PnP: peak negative pressure; qCEUS:
quantitative contrast enhanced ultrasound; RBC: red
blood cell; RBV: relative blood volume; ROI: region of
interest; RR: reperfusion rate; Sono: sonopermeation;
TUNEL: terminal deoxynucleotidyl transferase dUTP
nick end labeling; UCA: ultrasound contrast agent;
US:
ultrasound;
UTMD:
ultrasound-triggered
microbubble destruction.

Supplementary Material
Supplementary methods and figures.
http://www.thno.org/v10p8143s1.pdf

Acknowledgements
We would like to acknowledge Kulsoom Javed
in the lab of Dr. Kenneth Hoyt for help with culturing
NGP tumors.
We would like to acknowledge Darrell
Yamashiro for his expertise on neuroblastoma.
We would like to acknowledge Vytas Bindokas
and the University of Chicago HTRC (Human Tissue
Resource Center) and Integrated Light Microscopy
core.
We would like to acknowledge Dr. Paul
Mountford for design and assembly of the lens and
cone system for generating focused ultrasound
(Supplementary Materials).
We would like to acknowledge Dr. Jake Dove
and Dr. Todd Murray at the University of Colorado
Boulder for providing the 2D mapping of the focused
transducer output (Supplementary Materials).
We would like to acknowledge Dr. Clark Meyer
for designing and 3D printing several components of
our 3D imaging apparatus.
We would like to acknowledge Ian Kampine for
assisting with the collection of temperature and
acoustic measurements.

8160

References
1.
2.
3.

4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.

Funding

24.

The work performed in this study has been
supported by the National Institute of Health through
the NIBIB and NCI (R21EB015040, R01CA235756,
R01CA238241, and 1R01CA199937), as well as the
Pediatric Cancer Foundation.
Dr. Laetsch is supported by the Norma and Jim
Smith Professorship of Clinical Excellence and Eugene
P. Frenkel, M.D. Scholarship in Clinical Medicine.

25.

Competing Interests
The authors have declared that no competing
interest exists.

26.
27.
28.
29.
30.
31.

Verissimo CS, Molenaar JJ, Fitzsimons CP, Vreugdenhil E. Neuroblastoma
therapy: what is in the pipeline? Endocr Relat Cancer. 2011; 18: R213–31.
Deyell RJ, Attiyeh EF. Advances in the understanding of constitutional and
somatic genomic alterations in neuroblastoma. Cancer Genet. 2011; 204: 113–
21.
Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Interleukin 2 with
anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with
high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised,
phase 3 trial. Lancet Oncol. 2018; 19: 1617–29.
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 Antibody with GM-CSF,
Interleukin-2, and Isotretinoin for Neuroblastoma. N Engl J Med. 2010; 363:
1324–34.
Park JR, Bagatell R, London WB, et al. Children’s Oncology Group’s 2013
blueprint for research: Neuroblastoma. Pediatr Blood Cancer. 2013; 60: 985–93.
Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related
cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013; 10:
697–710.
Bansal N, Adams MJ, Ganatra S, et al. Strategies to prevent
anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncol. 2019;
5: 18.
Matsumura Y, Maeda H. A New Concept for Macromolecular Therapeutics in
Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins
and the Antitumor Agent Smancs. Cancer Res. 1986; 46: 6387–92.
Noguchi Y, Wu J, Duncan R, et al. Early Phase Tumor Accumulation of
Macromolecules: A Great Difference in Clearance Rate between Tumor and
Normal Tissues. Jpn J Cancer Res. 1998; 89: 307–14.
Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor
blood vessels for drug delivery, factors involved, and limitations and
augmentation of the effect. Adv Drug Deliv Rev. 2011; 63: 136–51.
Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev
Clin Oncol. 2010; 7: 653–64.
Barenholz Y (Chezy). Doxil® — The first FDA-approved nano-drug: Lessons
learned. J Control Release. 2012; 160: 117–34.
Nichols JW, Bae YH. EPR: Evidence and fallacy. J Control Release. 2014; 190:
451–64.
Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails
in the clinic, what is the future of nanomedicine? J Control Release. 2016; 244:
108–21.
Prabhakar U, Maeda H, Jain RK, et al. Challenges and Key Considerations of
the Enhanced Permeability and Retention Effect for Nanomedicine Drug
Delivery in Oncology. Cancer Res. 2013; 73: 2412–7.
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology:
The impact of passive and active targeting in the era of modern cancer biology.
Adv Drug Deliv Rev. 2014; 66: 2–25.
Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors:
Principles, pitfalls and (pre-) clinical progress. J Control Release. 2012; 161:
175–87.
Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular
permeability; Where is the missing link? J Control Release. 2012; 164: 265–75.
Greish K, Nehoff H, Parayath N, Domanovitch L, Taurin S. Nanomedicine for
drug targeting: strategies beyond the enhanced permeability and retention
effect. Int J Nanomedicine. 2014; 2539.
Price RJ, Skyba DM, Kaul S, Skalak TC. Delivery of Colloidal Particles and Red
Blood Cells to Tissue Through Microvessel Ruptures Created by Targeted
Microbubble Destruction With Ultrasound. Circulation. 1998; 98: 1264–7.
Skyba DM, Price RJ, Linka AZ, Skalak TC, Kaul S. Direct In vivo Visualization
of Intravascular Destruction of Microbubbles by Ultrasound and its Local
Effects on Tissue. Circulation. 1998; 98: 290–3.
Ward M, Wu J, Chiu J-F. Ultrasound-induced cell lysis and sonoporation
enhanced by contrast agents. J Acoust Soc Am. 1999; 105: 2951–7.
Sirsi SR, Borden MA. Microbubble compositions, properties and biomedical
applications. Bubble Sci Eng Technol. 2009; 1: 3–17.
Sboros V. Response of contrast agents to ultrasound. Adv Drug Deliv Rev.
2008; 60: 1117–36.
Lammertink BHA, Bos C, Deckers R, Storm G, Moonen CTW, Escoffre J-M.
Sonochemotherapy: from bench to bedside. Front Pharmacol. 2015; 6: 1–17.
Böhmer MR, Klibanov AL, Tiemann K, Hall CS, Gruell H, Steinbach OC.
Ultrasound triggered image-guided drug delivery. Eur J Radiol. 2009; 70: 242–
53.
Lentacker I, De Cock I, Deckers R, De Smedt SC, Moonen CTW.
Understanding ultrasound induced sonoporation: Definitions and underlying
mechanisms. Adv Drug Deliv Rev. 2014; 72: 49–64.
Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured
cells by sonoporation in vitro. Ultrasound Med Biol. 1997; 23: 953–9.
Korpanty G, Chen S, Shohet RV, et al. Targeting of VEGF-mediated
angiogenesis to rat myocardium using ultrasonic destruction of microbubbles.
Gene Ther. 2005; 12: 1305–12.
Laing ST, Kim H, Kopechek JA, et al. Ultrasound-mediated delivery of
echogenic immunoliposomes to porcine vascular smooth muscle cells in vivo. J
Liposome Res. 2010; 20: 160–7.
Sirsi SR, Hernandez SL, Zielinski L, et al. Polyplex-microbubble hybrids for
ultrasound-guided plasmid DNA delivery to solid tumors. J Control Release.
2012; 157: 224–34.

http://www.thno.org

Theranostics 2020, Vol. 10, Issue 18

8161

32. Sirsi SR, Borden MA. Advances in Ultrasound Mediated Gene Therapy Using
Microbubble Contrast Agents. Theranostics. 2012; 2: 1208–22.
33. Lum AFH, Borden MA, Dayton PA, Kruse DE, Simon SI, Ferrara KW.
Ultrasound radiation force enables targeted deposition of model drug carriers
loaded on microbubbles. J Control Release. 2006; 111: 128–34.
34. Lentacker I, Geers B, Demeester J, De Smedt SC, Sanders NN. Design and
Evaluation of Doxorubicin-containing Microbubbles for Ultrasound-triggered
Doxorubicin Delivery: Cytotoxicity and Mechanisms Involved. Mol Ther.
2010; 18: 101–8.
35. Bing C, Rich M, Munaweera I, Chopra R. Characterization of different bubble
formulations for blood-brain barrier opening using a focused ultrasound
system with acoustic feedback control. Sci Rep. 2018; 8: 1–12.
36. Aryal M, Park J, Vykhodtseva N, Zhang Y-Z, McDannold N. Enhancement in
blood-tumor barrier permeability and delivery of liposomal doxorubicin using
focused ultrasound and microbubbles: evaluation during tumor progression
in a rat glioma model. Phys Med Biol. 2015; 60: 2511–27.
37. Theek B, Baues M, Ojha T, et al. Sonoporation enhances liposome
accumulation and penetration in tumors with low EPR. J Control Release.
2016; 231: 77–85.
38. Tinkov S, Coester C, Serba S, et al. New doxorubicin-loaded phospholipid
microbubbles for targeted tumor therapy: In-vivo characterization. J Control
Release. 2010; 148: 368–72.
39. Lin C-Y, Li J-R, Tseng H-C, Wu M-F, Lin W-L. Enhancement of focused
ultrasound with microbubbles on the treatments of anticancer nanodrug in
mouse tumors. Nanomedicine Nanotechnol Biol Med. 2012; 8: 900–7.
40. Wu S-Y, Tung Y-S, Marquet F, et al. Transcranial cavitation detection in
primates during blood-brain barrier opening-a performance assessment study.
IEEE Trans Ultrason Ferroelectr Freq Control. 2014; 61: 966–78.
41. Lucidarme O, Nguyen T, Kono Y, et al. Angiogenesis model for ultrasound
contrast research. Acad Radiol. 2004; 11: 4–12.
42. Stieger SM, Bloch SH, Foreman O, Wisner ER, Ferrara KW, Dayton PA.
Ultrasound assessment of angiogenesis in a matrigel model in rats. Ultrasound
Med Biol. 2006; 32: 673–81.
43. Thiele CJ. Neuroblastoma Cell Lines. J Human Cell Culture. 1998; 1: 21–53.
44. Banerjee D, Hernandez SL, Garcia A, et al. Notch Suppresses Angiogenesis
and Progression of Hepatic Metastases. Cancer Res. 2015; 75: 1592–602.
45. Kaya M, Gregory V TS, Dayton PA. Changes in Lipid-Encapsulated
Microbubble Population During Continuous Infusion and Methods to
Maintain Consistency. Ultrasound Med Biol. 2009; 35: 1748–55.
46. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification
of Myocardial Blood Flow With Ultrasound-Induced Destruction of
Microbubbles Administered as a Constant Venous Infusion. Circulation. 1998;
97: 473–83.
47. Prewett M, Huber J, Li Y, et al. Antivascular Endothelial Growth Factor
Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor
Angiogenesis and Growth of Several Mouse and Human Tumors. Cancer Res.
1999; 59: 5209–18.
48. Bing C, Patel P, Staruch RM, et al. Longer heating duration increases localized
doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU
mild hyperthermia and thermosensitive liposomal doxorubicin. Int J
Hyperthermia. 2019; 36: 195–202.
49. Head HW, Dodd GD, Bao A, et al. Combination Radiofrequency Ablation and
Intravenous
Radiolabeled
Liposomal
Doxorubicin:
Imaging
and
Quantification of Increased Drug Delivery to Tumors. Radiology. 2010; 255:
405–14.
50. Bergers G, Song S. The role of pericytes in blood-vessel formation and
maintenance. Neuro-Oncol. 2005; 7: 452–64.
51. Hernandez SL, Banerjee D, Garcia A, et al. Notch and VEGF pathways play
distinct but complementary roles in tumor angiogenesis. Vasc Cell. 2013; 5: 17.
52. Burke CW, Klibanov AL, Sheehan JP, Price RJ. Inhibition of glioma growth by
microbubble activation in a subcutaneous model using low duty cycle
ultrasound without significant heating. J Neurosurg. 2011; 114: 1654–61.
53. Eisenbrey JR, Merton DA, Marshall A, et al. Comparison of Photoacoustically
Derived
Hemoglobin
and
Oxygenation
Measurements
with
Contrast-Enhanced
Ultrasound
Estimated
Vascularity
and
Immunohistochemical Staining in a Breast Cancer Model. Ultrason Imaging.
2015; 37: 42–52.
54. Schultz CW, Liu J-B, Dhir T, et al. Selecting the Optimal Parameters for
Sonoporation of Pancreatic Cancer in a Pre-Clinical Model. IEEE Int Ultrason
Symp. 2019; 4: 328–31.

http://www.thno.org

